Article History
Received: 14 July 2023
Accepted: 30 August 2023
First Online: 29 September 2023
Declarations
:
: Eleonora Lad declares consultancy/scientific advisory boards of Roche, Novartis, Apellis, Allegro, Alexion, Annexon, Aspen Neuroscience, Broadwing Bio, Gemini Therapeutics, Retrotope, Galimedix, IVERIC Bio, NGM Biopharmaceuticals, Janssen, Thea Laboratoires, Nanoscope Therapeutics, Perceive Bio, and Osanni Bio, as well as research funding through Duke University from Roche, Novartis, Apellis, Neurotech, Alexion, IVERIC Bio, LumiThera, Gemini Therapeutics, Boehringer Ingelheim, NGM Biopharmaceuticals, and Janssen. Robert Finger declares research funding from Biogen; consultancy/advisory board for Apellis, Alimera, Bayer, Boehringer Ingelheim, Biogen, Novartis, Roche/Genentech, ODOS and ProGenerika. Robyn Guymer declares consultancy and/or advisory boards of Roche, Genentech, Apellis, Bayer, Novartis, Belite Bio, Character Bioscience, Boehringer Ingelheim Pharmaceuticals, Ocular Therapeutix.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.